<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18026" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Autoimmune Hepatitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Linzay</surname>
            <given-names>Catherine D.</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Bashar</given-names>
          </name>
          <aff>SUNY Upstate University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pandit</surname>
            <given-names>Sudha</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Catherine Linzay declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bashar Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sudha Pandit declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18026.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Autoimmune hepatitis refers to chronic and progressive inflammation of the liver from an unknown cause. The proposed mechanism for the development of autoimmune hepatitis is thought to be the interplay of genetic predisposition, an environmental trigger, and failure of the native immune system resulting in chronic inflammation of hepatocytes and subsequent fibrosis of the liver. There are two known types of autoimmune hepatitis. Type 1 is distinguished by the presence of anti-smooth muscle antibodies (ASMA) with or without anti-nuclear antibodies (ANA). Type 2 autoimmune hepatitis presents with positive anti-liver/anti-kidney microsome (anti-LMK) type 1 antibodies or anti-liver cytosol (anti-LC) type 1 antibodies. This activity reviews the pathophysiology, causes, presentation, and diagnosis of autoimmune hepatitis and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of autoimmune hepatitis.</p></list-item><list-item><p>Review the workup of a patient with autoimmune hepatitis.</p></list-item><list-item><p>Outline the treatment and management options available for autoimmune hepatitis.</p></list-item><list-item><p>Explain the interprofessional team strategies for improving care coordination and communication regarding the management of patients with autoimmune hepatitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18026&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18026">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18026.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Autoimmune hepatitis refers to chronic and progressive inflammation of the liver from an unknown cause. The proposed mechanism for the development of autoimmune hepatitis&#x000a0;is thought to be the interplay of genetic predisposition, an environmental trigger, and failure of the native immune system resulting in chronic inflammation of hepatocytes and subsequent fibrosis of the liver. <xref ref-type="bibr" rid="article-18026.r1">[1]</xref><xref ref-type="bibr" rid="article-18026.r2">[2]</xref><xref ref-type="bibr" rid="article-18026.r3">[3]</xref>There are two known types of&#x000a0;autoimmune hepatitis. Type 1 is distinguished by the presence of anti-smooth muscle antibodies (ASMA) with or without anti-nuclear antibodies (ANA). Type 2&#x000a0;autoimmune hepatitis&#x000a0;presents with positive anti-liver/anti-kidney microsome (anti-LMK) type 1 antibodies or anti-liver cytosol (anti-LC) type 1 antibodies.</p>
      </sec>
      <sec id="article-18026.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There is no specific evidence of the cause. Sixty percent of patients have chronic hepatitis but without serologic evidence of a viral infection. The disease is associated with anti-smooth muscle autoantibodies.&#x000a0;<xref ref-type="bibr" rid="article-18026.r4">[4]</xref></p>
      </sec>
      <sec id="article-18026.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Epidemiological data on&#x000a0;autoimmune hepatitis&#x000a0;is scarce and very likely unreported and underrecognized. Of the two types of&#x000a0;autoimmune hepatitis, 80% of cases are diagnosed as type 1. Seventy-five percent of type 1&#x000a0;autoimmune hepatitis&#x000a0;is known to manifest in young or middle-aged females.&#x000a0;Autoimmune hepatitis&#x000a0;is more common in females than&#x000a0;males with a ratio of 3.6:1. <xref ref-type="bibr" rid="article-18026.r5">[5]</xref><xref ref-type="bibr" rid="article-18026.r2">[2]</xref>&#x000a0;Due to the lack of exact epidemiological data, the true incidence and prevalence in the United States are&#x000a0;unknown. However, it is reported that 100,000 to 200,000 individuals are affected each year.&#x000a0; Based on European studies, the incidence of&#x000a0;autoimmune hepatitis&#x000a0;is 0.9-2/100,000 populations per year and the prevalence of 11-25/100,000 per year. Type 2 autoimmune hepatitis&#x000a0;is most commonly diagnosed in children and young adults and usually presents with fulminant hepatic failure.</p>
      </sec>
      <sec id="article-18026.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The etiology of&#x000a0;autoimmune hepatitis&#x000a0;is unknown. The current proposition for pathogenesis is thought to be secondary to a failure of immune tolerance in a genetically susceptible individual leading to a T-cell mediated inflammation caused by various environmental triggers. Common triggers include infections, medications, and toxins. Certain human leukocyte antigen (HLA) haplotypes are more susceptible to the development of&#x000a0;autoimmune hepatitis. Susceptible alleles are different in different ethnic groups. Among White North Americans and Northern Europeans, susceptible alleles are located on the short arm of chromosome 6, specifically within the region of DRB-1. Nitrofurantoin and minocycline are well-documented culprits of drug-induced&#x000a0;autoimmune hepatitis. Tumor necrosis factor-alpha drugs have been more recently linked to&#x000a0;autoimmune hepatitis.</p>
      </sec>
      <sec id="article-18026.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The hallmark histologic feature of&#x000a0;autoimmune hepatitis&#x000a0;is interface hepatitis. However, it is nondiagnostic as it is present&#x000a0;in most cases of viral hepatitis. Various histological findings are associated with&#x000a0;autoimmune hepatitis, but all of them are nonspecific.</p>
        <p>The specimen of liver biopsy should include 6 portal triads for&#x000a0;autoimmune hepatitis&#x000a0;diagnosis. Typical&#x000a0;autoimmune hepatitis&#x000a0;biopsy includes mononuclear inflammatory infiltrate mostly plasma cells, located primarily in the portal tracts. This inflammation leads to piecemeal necrosis of hepatocytes leading to the destruction of limiting plate (interface hepatitis), bridging fibrosis (connecting portal and central area of hepatocytes), regenerating nodules, and finally cirrhosis. Twenty-five percent of cases show changes in bile ducts such as ductopenia, cholangitis.</p>
        <p>These histologic findings are nonspecific for&#x000a0;autoimmune hepatitis. Thus, a scoring system was developed for the diagnosis of&#x000a0;autoimmune hepatitis. In 1993, the International Autoimmune Hepatitis Group (IAIHG) initially proposed criteria that classified patients as &#x0201c;probable&#x0201d; or &#x0201c;definite&#x0201d; for&#x000a0;autoimmune hepatitis&#x000a0;based on multiple factors: gender, the presence of transaminitis, the presence of autoantibodies, and a history of autoimmune disease in first-degree relatives. These criteria also took into account whether or not other causes such as viral or alcohol-induced hepatitis had been excluded. In 1999, the scoring system was updated to include response to treatment. Since that time, a simplified scoring system has been introduced and is more conducive to everyday use by clinicians. Using the new scoring system, the sensitivity and specificity for probable&#x000a0;autoimmune hepatitis&#x000a0;are 91% and 94%, respectively; the sensitivity and specificity of definite&#x000a0;autoimmune hepatitis&#x000a0;are 75.5% and 100%, respectively.</p>
      </sec>
      <sec id="article-18026.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Autoimmune hepatitis&#x000a0;can present in a variety of ways from an asymptomatic elevation of liver enzymes noted on routine lab tests to fulminant hepatitis. Clinical manifestations of&#x000a0;autoimmune hepatitis&#x000a0;depend on how acute liver disease is at presentation, the stage of inflammation, or the complication of liver cirrhosis. The most common features of&#x000a0;autoimmune hepatitis&#x000a0;are fatigue, malaise, jaundice, abdominal pain, and sometimes, arthralgias.</p>
        <p>Features of a failing liver such as ascites, hepatic encephalopathy, and variceal hemorrhage are a rare initial presentation of&#x000a0;autoimmune hepatitis. Only a few patients present with acute liver failure.&#x000a0;Autoimmune hepatitis&#x000a0;may present concurrently with other autoimmune diseases like Graves disease, rheumatoid arthritis, celiac disease, type I diabetes, ulcerative colitis, hemolytic anemia, and immune thrombocytopenia. Specifically,&#x000a0;autoimmune hepatitis&#x000a0;is present in approximately 10% of individuals with autoimmune polyendocrine syndrome type 1.</p>
        <p>About 25% of patients with&#x000a0;autoimmune hepatitis&#x000a0;are asymptomatic. The most common physical findings in&#x000a0;autoimmune hepatitis&#x000a0;are hepatomegaly (78%) and jaundice (69%) in patients with severe disease. Another common physical finding is splenomegaly with or without cirrhosis.</p>
      </sec>
      <sec id="article-18026.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Autoimmune hepatitis should be considered in all individuals with both acute and chronic liver disease. Diagnosis of&#x000a0;autoimmune hepatitis&#x000a0;requires exclusion of other chronic causes of liver disease including Wilson disease, drug-induced hepatitis, nonalcoholic hepatosteatosis (NASH), chronic viral hepatitis, primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC).<xref ref-type="bibr" rid="article-18026.r6">[6]</xref><xref ref-type="bibr" rid="article-18026.r7">[7]</xref><xref ref-type="bibr" rid="article-18026.r8">[8]</xref></p>
        <p>A multi-pronged approach is used to make a diagnosis. This approach includes&#x000a0;determining symptoms, laboratory tests, and biopsies, as no single diagnostic test is pathognomonic for&#x000a0;autoimmune hepatitis. Marked elevation of serum transaminases (AST, ALT) and gamma-globulin is common; elevation in alkaline phosphatase is less common.&#x000a0; The serum levels of AST, ALT, and gamma globulin reflect disease severity and immediate prognosis at presentation.</p>
        <p>The serologic markers required for the diagnosis of&#x000a0;autoimmune hepatitis&#x000a0;include antinuclear antibody (ANA), smooth muscle antibodies (SMA), and antibodies to liver-kidney microsome type 1 (anti-LKM1). Indirect immunofluorescence detects ANA, SMA, and anti-LKM1.&#x000a0; The diagnostic accuracy, specificity, and sensitivity of these markers are 74%, 99%, and 43%, respectively. Anti-liver cytosol type I, anti-soluble liver antigen (SLA) antibodies, and perinuclear antineutrophil cytoplasmic antibodies (pANCA) can also be associated with&#x000a0;autoimmune hepatitis. <xref ref-type="bibr" rid="article-18026.r9">[9]</xref>Conversely, anti-mitochondrial antibodies are more commonly seen with primary biliary cirrhosis and are usually absent in&#x000a0;autoimmune hepatitis; however, they can be present in those with overlapping syndromes. Atypical&#x000a0;perinuclear antineutrophil cytoplasmic antibodies&#x000a0;are commonly associated with type-1&#x000a0;autoimmune hepatitis&#x000a0;and&#x000a0;primary sclerosing cholangitis. Anti-LKM1 is common in type 2 AH autoimmune hepatitis&#x000a0;and is mainly observed in children.</p>
        <p>Anti-SLA antibodies are more useful from a prognostic standpoint as these are associated with more severe disease, treatment failure, and a higher relapse rate. Liver biopsy is required for both diagnosis and staging of&#x000a0;autoimmune hepatitis.</p>
      </sec>
      <sec id="article-18026.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment guidelines for&#x000a0;autoimmune hepatitis&#x000a0;are continually evolving. Untreated individuals develop cirrhosis and subsequently die of liver failure two years from diagnosis. <xref ref-type="bibr" rid="article-18026.r10">[10]</xref><xref ref-type="bibr" rid="article-18026.r11">[11]</xref><xref ref-type="bibr" rid="article-18026.r12">[12]</xref>&#x000a0;Nonetheless, a handful of cases are reported to have increasing and decreasing clinical stages and may even progress into prolonged spontaneous remission. Therapy for&#x000a0;autoimmune hepatitis&#x000a0;should begin in patients who fit any or all of the following criteria:</p>
        <list list-type="bullet">
          <list-item>
            <p>Elevated AST and ALT more than&#x000a0;ten times the upper limit of normal, or at least five times the&#x000a0;upper limit of normal</p>
          </list-item>
          <list-item>
            <p>Gamma globulin at least two times the&#x000a0;upper limit of normal&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Presence of bridging necrosis and multilobular necrosis in liver biopsy.</p>
          </list-item>
        </list>
        <p>It is now well established that the use of corticosteroids leads to complete remission and in most cases improves mortality. The American Association for the Study of Liver Diseases recommends monotherapy with prednisone or combination therapy with prednisone and azathioprine. However, due to multiple adverse effects of long-term use of prednisone, combination therapy is preferred over monotherapy with prednisone. Monotherapy with prednisone is preferred in cases of pregnancy, intolerance to azathioprine, an absence of thiopurine methyltransferase (TPMT) activity, or severe cytopenia. Immunosuppressive therapy should not be started in patients with preexisting comorbid conditions such as vertebral compression, brittle diabetes, uncontrolled hypertension, psychosis.</p>
        <p>For monotherapy, a typical induction dose of prednisone is 60 mg daily for 1 week followed by 40 mg in the second week, and 30 mg daily in the third and fourth week. The maintenance dose of prednisone is 20 mg daily until the endpoint or deep clinical remission. The prednisone should be tapered over time and eventually discontinued. The&#x000a0;American Association for the Study of Liver Diseases&#x000a0;recommends at least 3 years of treatment. Upon completion of prednisone, patients are classified as in remission, relapsed, or treatment failure based on their histological and laboratory response to steroids, and the presence or absence of clinical symptoms. Histologic regression lags by 3 to 6 months, so treatment must be continued despite normalization of liver enzymes.&#x000a0;For combination therapy, the induction dose of prednisone is 30 mg daily for 1 week, followed by 20 mg daily for 1 week, followed by 15 mg daily for 2 weeks. The maintenance dose is 10 mg daily until the endpoint. The dose of azathioprine in combination therapy for both induction and maintenance is 30 mg oral daily.&#x000a0;</p>
        <p>Budesonide may be used instead of prednisone to reduce the adverse effects associated with steroid treatment. The combination of budesonide and azathioprine is emerging as an alternative first-line therapy. In cases of inadequate or incomplete response, or azathioprine intolerance, mycophenolate mofetil, cyclosporine A, and tacrolimus can be used.</p>
        <p>Remission occurs when the patient becomes asymptomatic with normalization of inflammatory markers, transaminases, gamma globulin, and histological improvement in liver biopsy.</p>
        <p>Relapse can occur after a patient in remission stops therapy. About 50% of patients have disease relapse within 6 months of discontinuing therapy. Relapse is defined by the elevation of AST (three times the upper limit of normal), the reappearance of histological findings after discontinuing therapy.</p>
        <p>Liver cirrhosis can develop in about 7% to 40% of treated patients. The development of cirrhosis is associated with incomplete response, treatment failure, and multiple relapses. Once cirrhosis develops, upper endoscopy should be performed for esophageal varices surveillance. Regular screening for hepatocellular carcinoma should be done with biannual liver ultrasound and alpha-fetoprotein.&#x000a0;Overall, management of liver cirrhosis in&#x000a0;autoimmune hepatitis&#x000a0;is similar regardless of etiology.&#x000a0;&#x000a0;Finally, liver transplantation is considered the standard of care in patients presenting with fulminant hepatic failure or those with the progression of disease despite multiple lines of therapy. Patients are also encouraged to avoid alcohol, unregulated herbal supplements, and high amounts of dietary fats.</p>
      </sec>
      <sec id="article-18026.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Primary biliary cirrhosis</p>
          </list-item>
          <list-item>
            <p>Primary sclerosing cholangitis</p>
          </list-item>
          <list-item>
            <p>Hepatitis A</p>
          </list-item>
          <list-item>
            <p>Hepatitis B</p>
          </list-item>
          <list-item>
            <p>Hepatitis C</p>
          </list-item>
          <list-item>
            <p>Hepatitis D</p>
          </list-item>
          <list-item>
            <p>Hepatitis E</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18026.s11" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Prognosis can vary widely but appears to be most dependent on treatment. Several randomized, controlled trials have shown that untreated&#x000a0;autoimmune hepatitis&#x000a0;patients have a 5-year and 10-year survival rate of 50% and 10%, respectively. Sixty percent to 80% of patients will enter remission after the proposed duration of treatment. Approximately 50% of these patients will relapse requiring therapy resumption. Some patients require life-long immunosuppression. Treatment failure occurs in 10% of patients that undergo treatment with prednisone. For those who undergo liver transplantation, approximately a third of patients have a recurrence of&#x000a0;autoimmune hepatitis.</p>
      </sec>
      <sec id="article-18026.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and management&#x000a0;of autoimmune hepatitis are complex and best done by an interprofessional team that includes a gastroenterologist, pharmacist, internist, and hepatologist. Specialized gastrointestinal nurses assist in the care, education of the patient and family, and coordination of the treatment and follow-up. It is now well established that the use of corticosteroids leads to complete remission and in most cases improves mortality. The American Association for the Study of Liver Diseases recommends monotherapy with prednisone or combination therapy with prednisone and azathioprine. The pharmacist should educate the patients on all the potential complications of steroids and when to seek medical help. At the same time, the primary care provider and nurse practitioner should thoroughly examine the patient for worsening&#x000a0;of the liver condition.</p>
        <p>The prognosis for most patients with autoimmune hepatitis is guarded. While survival has improved over the past 2 decades, it still is low. Relapse of the condition is common and some patients may benefit from a liver transplant.<xref ref-type="bibr" rid="article-18026.r13">[13]</xref><xref ref-type="bibr" rid="article-18026.r14">[14]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-18026.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18026&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18026">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/autoimmune-hepatitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18026">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18026/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18026">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18026.s14">
        <title>References</title>
        <ref id="article-18026.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silva</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brito</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>INN</given-names>
              </name>
              <name>
                <surname>N&#x000f3;brega</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>MCSM</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>HDN</given-names>
              </name>
              <name>
                <surname>Fortes</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Pimentel</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mota</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Surlo</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Lyra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rocha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Santana</surname>
                <given-names>GO</given-names>
              </name>
            </person-group>
            <article-title>Frequency of Hepatobiliary Manifestations and Concomitant Liver Disease in Inflammatory Bowel Disease Patients.</article-title>
            <source>Biomed Res Int</source>
            <year>2019</year>
            <volume>2019</volume>
            <fpage>7604939</fpage>
            <pub-id pub-id-type="pmid">30834274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18026.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palle</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Naik</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>McCracken</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Kolachala</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Racial disparities in presentation and outcomes of paediatric autoimmune hepatitis.</article-title>
            <source>Liver Int</source>
            <year>2019</year>
            <month>May</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>976</fpage>
            <page-range>976-984</page-range>
            <pub-id pub-id-type="pmid">30802337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18026.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agbim</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Asrani</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers.</article-title>
            <source>Expert Rev Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>361</fpage>
            <page-range>361-374</page-range>
            <pub-id pub-id-type="pmid">30791772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18026.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doycheva</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Watt</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Gulamhusein</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune hepatitis: Current and future therapeutic options.</article-title>
            <source>Liver Int</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>1002</fpage>
            <page-range>1002-1013</page-range>
            <pub-id pub-id-type="pmid">30716203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18026.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puustinen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Barner-Rasmussen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pukkala</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>F&#x000e4;rkkil&#x000e4;</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland.</article-title>
            <source>Dig Liver Dis</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>51</volume>
            <issue>9</issue>
            <fpage>1294</fpage>
            <page-range>1294-1299</page-range>
            <pub-id pub-id-type="pmid">30850346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18026.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wehrman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waisbourd-Zinman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hilmara</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rand</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Steroid Free Treatment of Autoimmune Hepatitis in Selected Children.</article-title>
            <source>J Pediatr</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>207</volume>
            <fpage>244</fpage>
            <page-range>244-247</page-range>
            <pub-id pub-id-type="pmid">30723013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18026.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pape</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gevers</surname>
                <given-names>TJG</given-names>
              </name>
              <name>
                <surname>Belias</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mustafajev</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Vrolijk</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>van Hoek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bouma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>van Nieuwkerk</surname>
                <given-names>CMJ</given-names>
              </name>
              <name>
                <surname>Hartl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schramm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lohse</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Taubert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jaeckel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Manns</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Papp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stickel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Heneghan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Drenth</surname>
                <given-names>JPH</given-names>
              </name>
            </person-group>
            <article-title>Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>10</issue>
            <fpage>2068</fpage>
            <page-range>2068-2075.e2</page-range>
            <pub-id pub-id-type="pmid">30625402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18026.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalekos</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Koskinas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Papatheodoridis</surname>
                <given-names>GV</given-names>
              </name>
            </person-group>
            <article-title>Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis.</article-title>
            <source>Ann Gastroenterol</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-23</page-range>
            <pub-id pub-id-type="pmid">30598587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18026.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aljumah</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Al Jarallah</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Albenmousa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Khathlan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Zanbagi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Quaiz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Judaibi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nabrawi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Al Hamoudi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Alghamdi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fallatah</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis.</article-title>
            <source>Saudi J Gastroenterol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>7 Suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-S20</page-range>
            <pub-id pub-id-type="pmid">30264737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18026.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dyson</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>De Martin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dalekos</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Drenth</surname>
                <given-names>JPH</given-names>
              </name>
              <name>
                <surname>Herkel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hubscher</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lenzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Milkiewicz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oo</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Heneghan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lohse</surname>
                <given-names>AW</given-names>
              </name>
              <collab>IAIHG Consortium</collab>
            </person-group>
            <article-title>Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>49</volume>
            <issue>5</issue>
            <fpage>528</fpage>
            <page-range>528-536</page-range>
            <pub-id pub-id-type="pmid">30671977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18026.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Averbukh</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>GY</given-names>
              </name>
            </person-group>
            <article-title>Role of Biologics in the Development of Autoimmune Hepatitis: A Review.</article-title>
            <source>J Clin Transl Hepatol</source>
            <year>2018</year>
            <month>Dec</month>
            <day>28</day>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>402</fpage>
            <page-range>402-409</page-range>
            <pub-id pub-id-type="pmid">30637218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18026.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harrison</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gleeson</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)?</article-title>
            <source>Liver Int</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>610</fpage>
            <page-range>610-620</page-range>
            <pub-id pub-id-type="pmid">30667576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18026.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country.</article-title>
            <source>Liver Int</source>
            <year>2019</year>
            <month>May</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>985</fpage>
            <page-range>985-994</page-range>
            <pub-id pub-id-type="pmid">30821090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18026.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>ZQ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>AQ</given-names>
              </name>
            </person-group>
            <article-title>[Clinical and pathological characteristics and outcome of 46 children with autoimmune hepatitis].</article-title>
            <source>Zhonghua Er Ke Za Zhi</source>
            <year>2019</year>
            <month>Jan</month>
            <day>02</day>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-45</page-range>
            <pub-id pub-id-type="pmid">30630230</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
